Format

Send to

Choose Destination
Lung Cancer. 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18.

Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.

Author information

1
Medical University Innsbruck, Department of Internal Medicine V (Haematology and Oncology), Innsbruck, Austria; Tyrolean Cancer Research Institute, Innsbruck, Austria. Electronic address: florian.kocher@i-med.ac.at.
2
Medical University Innsbruck, Department of Internal Medicine V (Haematology and Oncology), Innsbruck, Austria; Wilhelminenspital Wien, Department of Internal Medicine I (Haematology and Oncology), Vienna, Austria.
3
Medical University Innsbruck, Department of Internal Medicine V (Haematology and Oncology), Innsbruck, Austria; Tyrolean Cancer Research Institute, Innsbruck, Austria.
4
Medical University Innsbruck, Department of Internal Medicine V (Haematology and Oncology), Innsbruck, Austria.
5
Medical University Innsbruck, Deportment of Visceral, Transplant and Thoracic Surgery, Innsbruck, Austria.
6
Paracelsus Medical University Salzburg, Department of Internal Medicine III (Haematology and Oncology), Salzburg, Austria.
7
Medical University Innsbruck, Department of Radiotherapy and Radiation Oncology, Innsbruck, Austria.
8
Medical University Innsbruck, Department of Pathology, Innsbruck, Austria.
9
University Hospital Basel, Institute of Pathology, Basel, Switzerland.
10
Academic Hospital Natters, Department of Pneumology, Natters, Austria.
11
General Hospital Kufstein, Department of Internal Medicine, Kufstein, Austria.
12
General Hospital Vipiteno, Department of Internal Medicine, Vipiteno, Italy.
13
Department of Clinical Epidemiology of TILAK/Cancer Registry of Tyrol, Innsbruck, Austria.

Abstract

INTRODUCTION:

The aim of this study was to describe a large consecutive cohort of non-small cell lung cancer (NSCLC) patients treated in daily routine within the last 25 years. An extensive list of general baseline characteristics (comorbidities, laboratory values, symptoms, performance state), NSCLC related factors (stage, histology), treatment related parameters (approach, applied therapies) and outcome (PFS, RFS, OS, perspective of decades) were analyzed in detail.

PATIENTS AND METHODS:

Medical files of 2293 consecutive NSCLC patients diagnosed between 1989 and 2009 at the Medical University of Innsbruck and affiliated hospitals were retrospectively analyzed. Patients were documented within our institution's comprehensive lung cancer project "Twenty-Year Retrospective of Lung Cancer (TYROL study)".

RESULTS:

Mean age at diagnosis was 64.1 years and 1611 patients (70.3%) were male. Most patients were diagnosed in stage IV (37.9%). The most frequent comorbidities present at diagnosis were cardiovascular disease (62.1%) and COPD (62.0%). The most common symptoms at diagnosis were coughing (54.7%) and dyspnea (45.3%). Of all 2293 patients 1981 (86.4%) received adequate antineoplastic treatment. In total 874 patients were radically operated, 119 received radiotherapy/radio-chemotherapy and the majority of patients (n=1278) were treated in palliative intent. A 2nd, 3rd, 4th and 5th-line palliative therapy was administered to 612, 278, 102, and 36 patients. Median OS, RFS and PFS were 16.4 months, 86.4 months and 5.1 months, respectively. A multitude of factors was associated with all three outcome variables. Of note, outcome has improved stepwise in the recent decade based on increased response rates leading to prolonged OS.

CONCLUSION:

This work incorporates most clinical aspects relevant in the treatment of NSCLC and beyond. Therefore, this comprehensive analysis provides a definite benchmark for prognostication and epidemiology of NSCLC in a Western European society.

KEYWORDS:

Comorbidities; Comprehensive; Non-small cell lung cancer (NSCLC); Outcome; Registry; Symptoms

PMID:
25564398
DOI:
10.1016/j.lungcan.2014.12.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center